Tobacco smoke induced COPD/emphysema in the animal model—are we all on the same page? by Maike Leberl et al.
REVIEW ARTICLE
published: 15 May 2013
doi: 10.3389/fphys.2013.00091
Tobacco smoke induced COPD/emphysema in the animal
model—are we all on the same page?
Maike Leberl , Adelheid Kratzer† and Laimute Taraseviciene-Stewart*
Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado School of Medicine, Denver, CO, USA
Edited by:
Michael Borchers, University of
Cincinnati College of Medicine, USA
Reviewed by:
Michael Borchers, University of
Cincinnati College of Medicine, USA
Peter Di, University of Pittsburgh,
USA
*Correspondence:
Laimute Taraseviciene-Stewart,
Division of Pulmonary Sciences and
Critical Care Medicine, Department
of Medicine, University of Colorado
School of Medicine, Anschutz
Medical Campus, Denver, CO
80262, USA.
e-mail: Laima.Taraseviciene@
ucdenver.edu
†Present address:
Adelheid Kratzer, Institute of
Physiology/Cardiovascular Research,
University of Zurich, Zurich,
Switzerland.
Chronic Obstructive Pulmonary Disease (COPD) is one of the foremost causes of death
worldwide. It is primarily caused by tobacco smoke, making it an easily preventable
disease, but facilitated by genetic α-1 antitrypsin deficiency. In addition to active smokers,
health problems also occur in people involuntarily exposed to second hand smoke (SHS).
Currently, the relationship between SHS and COPD is not well established. Knowledge of
pathogenic mechanisms is limited, thereby halting the advancement of new treatments
for this socially and economically detrimental disease. Here, we attempt to summarize
tobacco smoke studies undertaken in animal models, applying both mainstream (direct,
nose only) and side stream (indirect, whole body) smoke exposures. This overview
of 155 studies compares cellular and molecular mechanisms as well as proteolytic,
inflammatory, and vasoreactive responses underlying COPD development. This is a
difficult task, as listing of exposure parameters is limited for most experiments. We
show that both mainstream and SHS studies largely present similar inflammatory cell
populations dominated by macrophages as well as elevated chemokine/cytokine levels,
such as TNF-α. Additionally, SHS, like mainstream smoke, has been shown to cause
vascular remodeling and neutrophil elastase-mediated proteolytic matrix breakdown with
failure to repair. Disease mechanisms and therapeutic interventions appear to coincide in
both exposure scenarios. One of the more widely applied interventions, the anti-oxidant
therapy, is successful for both mainstream and SHS. The comparison of direct with
indirect smoke exposure studies in this review emphasizes that, even though there
are many overlapping pathways, it is not conclusive that SHS is using exactly the
same mechanisms as direct smoke in COPD pathogenesis, but should be considered a
preventable health risk. Some characteristics and therapeutic alternatives uniquely exist in
SHS-related COPD.
Keywords: second hand cigarette smoke, COPD, emphysema, inflammation, animal model, chamber, pulmonary
hypertension, matrix degradation
INTRODUCTION
Cigarette smoke is the main preventable cause for chronic
obstructive pulmonary disease (COPD), resulting in progressive
proteolytic, inflammatory, and vasoactive responses that lead to
emphysema, small airway obstruction, and pulmonary hyperten-
sion. COPD in itself is a serious burden throughout the world,
both economically and socially, costing $193 billion in the United
States alone (CDC, 2008). The disease is the third largest cause
of death in the United States and the fourth worldwide (Pauwels
et al., 2001; Minino, 2010). An estimated 95% of COPD cases are
attributed to smoking (Barnes et al., 2003), while only a relatively
small margin of smokers is susceptible (Fletcher and Peto, 1977).
The United States Centers for Disease Control and Prevention
considers tobacco smoke to be “the single most important pre-
ventable risk to human health in developed countries and an
important cause of premature death worldwide,” not only to
smokers, but also to those involuntary exposed to second hand
smoke (SHS or environmental tobacco smoke, known as ETS)
(Oberg et al., 2011).
There are three kinds of smoke that humans are exposed
to: mainstream or first hand smoke that is directly inhaled
through a person’s mouth after taking a puff on a lit cigarette;
Side stream smoke, which goes into the air directly from a
burning cigarette, cigar, or smoking pipe; and SHS, which is a
combination of both, side stream smoke being the main com-
ponent of SHS, also known as ETS. Cigarette smoke thereby
not only affects smokers, but also contributes to health prob-
lems in non-smokers. While a smoker voluntarily inhales the
first hand smoke, the non-smoker is inadvertently exposed to
SHS that comes from the burning end of a cigarette and the
smoke exhaled by the smoker. SHS is therefore also a poten-
tial risk factor for COPD and entails symptomatic disease in
individuals who are not actually smokers. At present, the dose-
response relationship between SHS exposure and COPD is
not well established and there is limited understanding of the
mechanisms responsible for its pathogenesis, thus halting the
development of new advanced treatments for this detrimental
disease.
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This review is an attempt to sort out the cigarette smoke expo-
sure studies according to levels (low/high) and manner (main-
stream or whole body) of the exposure, focusing largely on newer
studies applying the rodent model.
SECOND HAND CIGARETTE SMOKE EXPOSURE
While the qualitative composition of the components is nearly
identical in mainstream smoke, side stream smoke, and SHS,
the quantitative composition of each is different. In the enclosed
environment, due to relatively low ventilation rates (Lofroth,
1989; Jinot and Bayard, 1994), some compounds are emit-
ted at levels up to more than 10 times greater in side stream
smoke and SHS when compared with mainstream smoke
(Moritsugu, 2007). Side stream smoking has therefore been
classified as a Class A carcinogen by the US Environmental
Protection Agency. Still, data regarding the biological evi-
dence linking SHS exposure and COPD are scarce. A 2006
US Surgeon General Report on the health consequences of
SHS concluded that the evidence linking SHS and COPD is
suggestive (www.surgeongeneral.gov/library/secondhandsmoke),
but not sufficient, to infer a causal relationship. The conclusion
of the report was drawn primarily from dated epidemiologic evi-
dence that did not establish a biological link (Hirayama, 1981;
Kalandidi et al., 1987; Sandler et al., 1989; Robbins et al., 1993;
Dayal et al., 1994; Leuenberger et al., 1994; Piitulainen et al., 1998;
Berglund et al., 1999). A very recent retrospective analysis of data
from 192 countries was published in 2011 and shows that world-
wide 40% of children, 33% of male non-smokers, and 35% of
female non-smokers are exposed to SHS (Oberg et al., 2011). In
2004 alone, 603,000 deaths were attributable to SHS, accounting
for approximately 1% of worldwide mortality. For this reason, the
US Surgeon General Report’s conclusion should be challenged by
providing evidence that SHS exposure can in fact cause COPD by
utilizing and comparing animalmodels as well as assessing patient
exposure to SHS.
THE ANIMAL MODEL AND EXPOSURE SYSTEM
In order to gain insight into the mechanisms of disease develop-
ment during cigarette smoke exposure, both mainstream and sec-
ond hand, animal models have been of exceptional use. Animals
are exposed to cigarette smoke in a smoking apparatus for either
mainstream (nose or head only) or side stream (whole body)
applications. In addition, smoke can either be filtered or not,
which either depends on the cigarette used (with a filter or with-
out) or the set-up of the apparatus. Another diversity factor is
the selection of different animal species with varying suscepti-
bilities, which can be particular to each strain within a species.
Early studies of SHS used self-constructed chambers for labora-
tory animals, allowing environmental smoke to diffuse within a
confined space in which the animals were kept. These chambers,
unique to each group, did not have the capabilities to measure
the parameters essential for assessing cigarette smoke dose and
composition. Also, the number and type of cigarettes as well as
the length of exposure varied in each study as much as they do
today, adding to the difficulty of comparing results. Generally,
standardized research-grade cigarettes should be used to eas-
ily define a specified dose of total suspended particles (TSP)
or total particulate matter (TPM), including nicotine and car-
bon monoxide levels. Standardized cigarettes became available
for worldwide use in 1969 (Roemer et al., 2012) and are most
commonly from the University of Kentucky (http://www.ca.uky.
edu/refcig/), although there are still often publications using non-
reference cigarettes. The introduction of the Teague chamber in
1994 (Teague et al., 1994) has revolutionized the field by allowing
maintenance of consistent levels of TSP/TPM that can be set at a
variety of concentrations for the exposure of animals to SHS that
can mimic human exposures.
In human exposure studies, only the distribution of fine par-
ticles (PM2.5, which are under 2.5μm in size and are able to
reach the alveoli of the lung) is measured. This accounts for only
a small fraction (about 0.1%) of the TSP measurements that
are usually reported in animal studies. Data from 66 US casinos
with smoking in California, Delaware, Nevada, New Jersey, and
Pennsylvania, developed PM2.5 frequency distributions, compar-
ing them with three non-smoking casinos. Geometric means for
PM2.5 were 53.8μg/m3 (range 18.5–205μg/m3) inside smok-
ing casinos, 4.3μg/m3 (range 0.26–29.7μg/m3) outside those
casinos, and 3.1μg/m3 (range 0.6–9μg/m3) inside the three non-
smoking casinos (Jiang et al., 2010; Lu et al., 2011; Repace et al.,
2011; Cochran et al., 2012).
Most commonly for SHS studies listed in Table 2, the Teague
chamber was set to exposures between 70 and 150mg/m3.
Concurrently, the mainstream smoke exposures listed in Table 1
were as low as 75mg/m3 and as high as 600mg/m3 TSP/TPM
(Hodge-Bell et al., 2007). Most of the mainstream smoke stud-
ies were performed at 140mg/m3 TSP/TPM levels (Table 1).
Ideally, more recent protocols should thereby produce results
that can compare the assessed proteolytic, inflammatory, and
vasoactive reaction based on similar exposure methods, duration,
and cigarette content. This can only be achieved if researchers
pertain to the standard procedures available today, such as
the use of reference cigarettes in a chamber with defined set-
tings for exposure. These conformities are essential, since a
majority of studies are performed in rodents (mice, rats, and
guinea pigs), where there is an overwhelming assortment of
strains with varying susceptibility, especially when considering
mice.
Today, rodents are the most commonly used models. While
mice are surely favored for their wide variety of applicable gene
expression manipulations, it remains difficult to standardizemea-
surements of pulmonary function to assess disease parameters.
The guinea pig model is also occasionally applied, mainly by one
group of investigators (Simani et al., 1974; Wright and Churg,
1990, 2002; Wright and Sun, 1994, 1999; Wright et al., 2002,
2011) though increased inflammatory cells and muscularization
of pulmonary vessels was recently documented (Dominguez-
Fandos et al., 2012). The rat is a favorable model, since mea-
surable emphysematous changes which further progress can be
detected after only 2 months of smoke exposure (Kratzer et al.,
2013).
Mainstream smoke and SHS exposure studies are summarized
in Tables 1, 2, respectively. Animal studies with an unidentified
smoke exposure are presented in Table 3. The cigarette brands
used are listed in Table 4.
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Table 1 | Mainstream cigarette smoke exposure modeled in animals.
Species/strain Cigarette
type
Dose and exposure TSP/TPM
(mg/m3)
Nicotine
(mg/m3)
CO (ppm) Copd/emphysema Remarks References
Guinea pig X 2× 20ml puffs/min,
8–9min/cig, 10min rest,
10/day; 1–60 days
X X X Simani et al., 1974
Sprague-Dawley rat X 12 s puffs, 4 s rest,
2/day, 5 day/week; 25
days
X 1.5mg/cig X Mainstream presumed Pittilo et al., 1982
Wistar rat nicorandil
p.o.
Seven star
unfiltered
30 cig, 2 s puff, 15
puffs/min, 8min
X 1.88% X Mainstream presumed Gomita et al., 1990
Rat X 8 cig X 1.5mg/cig X “Whole smoke”;
mainstream presumed;
exposure as in Pittilo et al.
(1982)
Pittilo et al., 1990
Guinea pig Commer-cial
unfiltered
10/day, 5 day/week;
1–12 month
X X X Emphysema (age and
exposure dependent)
mainstream presumed;
exposure as in Simani et al.
(1974)
Wright and Churg,
1990
Wistar rat Long peace 2× 20min, 15
puffs/min; 21 days
X 2mg/cig X Hamburg II; exposure as in
Gomita et al. (1990)
Suemaru et al.,
1992
Sprague-dawley rat Commercial
unfiltered
7/day; 1–7 days X X X PH “Whole smoke”; exposure
as in Simani et al. (1974)
Sekhon et al., 1994
Guinea pig X 10/day, 5 day/week; 4–8
months
X X 5% CHG Emphysema and
arteriole
muscularization
Exposure as in Wright and
Churg (1990)
Wright and Sun,
1994
C57Bl/129 MMP-12
KO with i.t. MCP-1
KY unfiltered 2/day, 6 days/week; 6
months
X X 10–14%
CHG
100% protected Mainstream presumed;
exposure as in Wright and
Churg (1990)
Hautamaki et al.,
1997
C57Bl/129 MMP-12
KO
KY unfiltered 2/day, 6 days/week; 6
month
X X 10–14%
CHG
100% protected Mainstream presumed;
exposure as in Wright and
Churg (1990)
Hautamaki et al.,
1997
Sprague-Dawley rat X 20ml/10min, 7/day, 5
days/week; 2–12
months
X X 4% CHG Exposure as in Wright and
Churg (1990)
Wright et al., 1997
Cam hartley guinea
pig
Commercial
unfiltered
7/day, 5 days/week; 6
months
X X X COPD and PH Exposure as in Wright and
Churg (1990)
Yamato et al., 1997
Sprague-Dawley rat Unfiltered 10/day, 5 day/week; 1–6
months
X X 10.1±
1.5% CHG
Emphysema Exposure as in Simani et al.
(1974)
Ofulue et al., 1998
Sprague-Dawley rat
PMN Ab
Unfiltered 10/day, 7 days/week; 2
months
X X X Emphysema Ofulue and Ko,
1999
Sprague-Dawley rat
MoMac Ab
Unfiltered 10/day, 7 day/week; 2
months
X X X Protected Ofulue and Ko,
1999
Sprague-Dawley rat X 10/day; 24 h X 1.1mg/cig 11mg/cig Small airway
constriction
Exposure as in Wright et al.
(1997)
Wright et al., 1999
Guinea pig Canada
Tobacco
unfiltered
7/day, 5 day/week;
24h-4 months
X 1.1mg/cig 11mg/cig Pulmonary arteriole
musculariza-
tion/hyperplasia
“Whole smoke” Wright and Sun,
1999
C57Bl/6 × DBA/2
hexavalent chromium
i.p.
Commercial
Arda-Bulgar-
tabac
filtered
50ml/cig, 10min ×
9/day; 5 days
533 1.6mg/cig X “Whole body mainstream” Balansky et al.,
2000
C57Bl/6 KY 2R1 2/day or 1–3/day; 6–48 h X X X Emphysema via
neutrophil elastase
“Whole smoke”; exposure
as in Sekhon et al. (1994)
Dhami et al., 2000
C57Bl/6 PMN Ab KY 2R1 2/day or 1–3/day; 6–48 h X X X Reduced emphysema “Whole smoke”; exposure
as in Sekhon et al. (1994)
Dhami et al., 2000
C57Bl/6 A1AT i.p. KY 2R1 2/day or 1–3/day; 6–48 h X X X Protected “Whole smoke”; exposure
as in Sekhon et al. (1994)
Dhami et al., 2000
(Continued)
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Table 1 | Continued
Species/strain Cigarette
type
Dose and exposure TSP/TPM
(mg/m3)
Nicotine
(mg/m3)
CO (ppm) Copd/emphysema Remarks References
C57Bl/129 TNFR KO
and 129J
KY 2R1 4/day; 24 h X X X Protected “Whole smoke”; exposure
as in Dhami et al. (2000)
Churg et al., 2002a
C57Bl/129
metallo-protease
inhibitor RS113456
KY 2R1 4/day; 24 h X X X Protected “Whole smoke”; exposure
as in Sekhon et al. (1994)
Churg et al., 2002b
C57Bl/129 MME Tg KY 2R1 4/day; 24 h X X X Emphysema “Whole smoke”; exposure
as in Sekhon et al. (1994)
Churg et al., 2002b
C57Bl/129 MME KO KY 2R1 4/day; 24 h X X X Protected “Whole smoke”; exposure
as in Sekhon et al. (1994)
Churg et al., 2002b
Hartley guinea pig
p.o. serine elastase
inhibitor ZD0892
KY 2R1 20ml/1.5min, 5/day, 5
day/week; 1 day- 6
months
X X X 45% protected “Whole smoke”; exposure
as in Wright and Sun (1999)
Wright et al., 2002
Hartley guinea pig Canada
Tobacco
unfiltered
20 puff/cig, 10/day, 5
day/week; 4–8 months
X 1.1mg/cig 11mg/cig Partial recovery after
cessation
Exposure as in Wright and
Sun (1994)
Wright and Churg,
2002
C57Bl/129 MMP-12
KO
KY 2R1 4 in 1h; 2–24h (harvest) X X X No emphysema “Whole smoke” Churg et al., 2003a
C57Bl/6 CD-1 α1
antitrypsin (prolastin)
KY 2R1 2/day, 5 day/week; 6
months
X X X 67% protected “Whole smoke”; exposure
as in Sekhon et al. (1994)
Churg et al., 2003b
C57Bl/6 NE KO KY unfiltered 2/day, 6 day/week; 6
months
X X 10% CHG 59% protected Mainstream presumed;
exposure as in Hautamaki
et al. (1997)
Shapiro et al., 2003
C57Bl/6 MMP-12 KO KY unfiltered 2/day, 6 day/week; 6
months
X X 10% CHG 100% protected Mainstream presumed;
exposure as in Hautamaki
et al. (1997)
Shapiro et al., 2003
C57Bl/129 TNFR KO KY 2R1 4/day, 5 day/week; 6
months
X X X 71% protected “Whole smoke”; exposure
as in Churg et al. (2002b)
Churg et al., 2004
SHR and
Wistar-Kyoto rat
Long Peace
filtered
23 (5 rat), 26, 30/day
(10 rat) 20min/day, 5
day/week; 8–14 weeks
X 1.9mg/cig X Hamburg II; exposure as in
Suemaru et al. (1992)
Tanaka et al., 2004
Balb/C SCID KY 2R4F
unfiltered
5 cig × 4/day, 30min
rest, 5 day/week
(1. week 1/day); 5
weeks-6 months
X X 8.3± 1.4
CHG
Emphysema Exposure as in D’Hulst et al.
(2005b)
D’Hulst et al.,
2005a
C57Bl/6 KY 1R3 5 cig × 4/day, 30min
rest, 5 day/week; 1
day-24 weeks
X X X Inflammatory cells
progressively
accumulate
Mainstream presumed
(Kobayashi chamber)
D’Hulst et al.,
2005b
Sprague-Dawley rat
Simvastatin
Eighty Eight
Lights South
Korea
10/day; 16 weeks X X X 100% protected “Whole smoke”;
mainstream presumed;
exposure as in Pittilo et al.
(1990)
Lee et al., 2005
Balb/C ovalbumin i.p.
d0 and d7
KY 1R3 5 cig × 4/day, 5
day/week; 10 days
X X X Airway inflammation Moerloose et al.,
2005
C57Bl/6J KY 2R1 2 × 2/day, 10 puffs each,
5 day/week; 2–6 months
X X X Progressive
emphysema
van der Strate
et al., 2006
Hartley guinea pig
MMP-9/-12 inhibitor
AZ11557272
KY 2R1 7/day, 5 day/week;
1–6 months
X X X 68% protected (70%
against SAR)
Mainstream presumed;
exposure as in Wright and
Churg (1990)
Churg et al., 2007a
C57Bl/6 and ICR KY 2R4F 2 h/day, 5 day/week;
6 months
75, 250,
600
X X Mild emphysema Hodge-Bell et al.,
2007
C57Bl/6 IL-18Ra KO KY 2R4
unfiltered
2 × 2/day, 5 day/week;
6 months
X X X 51% protected Mainstream presumed;
exposure as in Hautamaki
et al. (1997)
Kang et al., 2007
(Continued)
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Table 1 | Continued
Species/strain Cigarette
type
Dose and exposure TSP/TPM
(mg/m3)
Nicotine
(mg/m3)
CO (ppm) Copd/emphysema Remarks References
C57Bl/6 CD8 KO KY unfiltered 2/day, 6 day/week;
6 months
X X 10% CHG 100% protected Mainstream presumed;
exposure as in Hautamaki
et al. (1997)
Maeno et al., 2007
C57Bl/6 CD4 KO KY unfiltered 2/day, 6 day/week;
6 months
X X 10% CHG Emphysema Mainstream presumed;
exposure as in Hautamaki
et al. (1997)
Maeno et al., 2007
FVB MrpI/MdrIa/Ib
KO
KY 2R1 2 cig × 2/day, 10 puffs
each, 5 day/week;
6 months
X X X No emphysema or
inflammation
van der Deen et al.,
2007
C57Bl/6J influenza or
viral PAMP
KY 2R4
unfiltered
1. week 0.5 cig × 2/day
2. week 1 cig × 3/day
X X X Accelerated
emphysema
Mainstream presumed;
exposure as in Hautamaki
et al. (1997)
Kang et al., 2008
C57Bl/6 KY 1R3 2 or 4 cig 5 day/week;
2–6 months
X X X T and B lymphocyte
response
Exposure as in Simani et al.
(1974); Hautamaki et al.
(1997)
Zavitz et al., 2008
C57Bl/6 i.p. caspase
inhibitor
KY 2R1 4/day acute or 3/day, 5
day/week; 24 h
X X X 100% protected “Whole smoke”;
mainstream presumed
Churg et al., 2009a
C57Bl/6 TNFR KO KY 2R1 4/day acute or 3/day,
5d/week; 6 months
X X X 83% protected (100%
against SAR)
“Whole smoke”;
mainstream presumed
Churg et al., 2009b
C57Bl/6 IL-1R KO KY 2R1 4/day acute or 3/day, 5
day/week; 24 h-6
months
X X X 65% protected (100%
against SAR)
“Whole smoke”;
mainstream presumed
Churg et al., 2009b
C57Bl/6 KY 2R1 4/day acute or 3/day, 5
day/week; 2 h-6 months
X X X Emphysema “Whole smoke”;
mainstream presumed
Churg et al., 2009b
C57Bl/6
clarithro-mycin p.o.
KY unfiltered 2/day, 6 day/week;
6 months
X X X Reduced emphysema Mainstream presumed;
exposure as in Hautamaki
et al. (1997); Shapiro et al.
(2003)
Nakanishi et al.,
2009
C57Bl/6J curcumin
p.o.
Commercial
filtered
Marlboro
12 puffs/min,
60min/day, 10 day or 5
day/week; 10 day-12
weeks
971±
98.3 in
5% CS
1mg/cig
104.5±
49.3 ng/ml
cotinin
X Reduced emphysema Suzuki et al., 2009
C57Bl/6 MMP-9 KO KY 3R4F
unfiltered
4/day, 6 day/week; 6
months
X X X Emphysema Exposure as in Hautamaki
et al. (1997)
Atkinson et al.,
2010
C57Bl/6 adipo-nectin
KO
KY 2R4F 35ml puff/25 s,
5min/cig, 2/day, 5
day/week; 6 months
173± 5.3
(100–250)
2.45
mg/cig
X Reduced emphysema
and inflammation
Miller et al., 2010
C57Bl/6J SOD3 Tg KY 3R4F 2× 1h/day; 3
day-6 months
300
(3 day) or
100
(month)
X X Reduced emphysema Yao et al., 2010
C57Bl/6J iNOS KO KY 3R4F 6h/day, 5 day/week; 8
months
140 X X Protected
emphysema and PH
Seimetz et al., 2011
C57Bl/6J eNOS KO KY 3R4F 6h/day, 5 day/week; 8
months
140 X X Emphysema and PH Seimetz et al., 2011
C57Bl/6J iNOS
inhibitor L-NIL
KY 3R4F 6h/day, 5 day/week; 8
months
140 X X Protected
emphysema and PH
Seimetz et al., 2011
Hartley guinea pig
AZD9668 NE inhibitor
p.o.
KY R21 2h/day, 5 day/week; 24
weeks
X X X Protected
emphysema and SAR
Exposure as in Churg et al.
(2007a)
Stevens et al., 2011
Hartley guinea pig
simvastatin
KY 2R1 and
2R4F
5/day, 5 day/week; 6
months
X X X Protected PH and
emphysema, not SAR
Exposure as in Barnes
(1990) (review)
Wright et al., 2011
Hartley guinea pig
MPO inhibitor AZ1
KY 2R1 5/day, 5 day/week; 6
months
X X X Reduced emphysema,
SAR, PH
Mainstream presumed;
exposure as in Simani et al.
(1974)
Churg et al., 2012
(Continued)
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Table 1 | Continued
Species/strain Cigarette
type
Dose and exposure TSP/TPM
(mg/m3)
Nicotine
(mg/m3)
CO (ppm) Copd/emphysema Remarks References
Hartley guinea pig KY 1R3F
unfiltered
7/day, 5 day/week; 3–6
months
X X X COPD Dominguez-Fandos
et al., 2012
C57Bl/6 KY 2R1 4/day; 24 h X X X Exposure as in Churg et al.
(2003b)
Preobrazhenska
et al., 2012
C57Bl/6 Marlboro
100
4/day 4–5min, 5
day/week; 5 s puff,
10min rest; 4 months
X X X Emphysema ”Active smoke“ Shan et al., 2012
C57Bl/6 IL17a KO Marlboro
100
4/day 4–5min, 5
day/week; 5 s puff,
10min rest; 4 months
X X X Reduced emphysema ”Active smoke“ Shan et al., 2012
C57Bl/6 IL17a Tg Marlboro
100
4/day 4–5min, 5
day/week; 5 s puff,
10min rest; 4 months
X X X Exacerbated
emphysema
”Active smoke“ Shan et al., 2012
C57Bl/6 Tcrd KO Marlboro
100
4/day 4–5min, 5
day/week; 5 s puff,
10min rest; 4 months
X X X Exacerbated
emphysema
”Active smoke“ Shan et al., 2012
C57Bl/6 Spp1 KO Marlboro
100
4/day 4–5min, 5
day/week; 5 s puff,
10min rest; 6 months
X X X Reduced emphysema ”Active smoke“ Shan et al., 2012
Mouse eNOS KO KY 2R1 and
2R4F
5/day, 5 day/week; 6
months
X X X Pulmonary
hypertension, COPD
Exposure as in Barnes
(1990) (review)
Wright et al., 2012
Balb/C Marlboro red 9 cig/day, 10 s CS and
50 s fresh air; 4 days
X 1mg/cig X Nemmar et al.,
2013
CHG, carboxyhemoglobin; PH, pulmonary hypertension; SAR, small airway remodeling. Cigarette brand names are in bold.
CHRONIC CIGARETTE SMOKE EXPOSURE
It is important to differentiate acute versus chronic smoke expo-
sure in respect to lung structure and function (Martin and
Tamaoka, 2006). Though both models induce airway narrowing
to a certain extent, the inflammation seen initially diminishes
during the time-course of exposure, along the lines of early repair
and late-stage failure to repair (Churg and Wright, 2009; Kratzer
et al., 2013). Mechanisms of repair seem to be sufficient for the
first month of cigarette smoke exposure, but since lesions change
over the exposure time, it is predicted that the pathological mech-
anisms differ in acute and chronic cases. Acute models can be as
short as 24 h or last up to as many as 2 weeks, while chronic mod-
els should be standardized to 6 months (24 weeks) of exposure to
induce the anatomical changes characterizing COPD (Churg and
Wright, 2009). Both acute and chronic cigarette smoke exposure
lead to oxidant stress, which pathologically affects airway cells to
promote remodeling (Martin and Tamaoka, 2006).
Since COPD can only manifest the pathological characteris-
tics seen in humans after long-term cigarette smoke exposure,
animals are often utilized in chronic studies to relate to the
human disease. Emphysema, airway remodeling and pulmonary
hypertension, which progress over time, can only be induced in
chronic models where structural alterations occur. Irreversible
matrix destruction, fibrosis, airway wall thickening, and hyper-
plasia of smooth muscle and goblet cells as well as fibroblasts
can only be seen in chronic cigarette exposure. Since COPD in
smoking patients is typically GOLD (Global Initiative for Chronic
Obstructive Lung Disease) stage III or IV and less commonly I
and II (Retamales et al., 2001), animal models must attempt to
mimic this by developing emphysema, small airway remodeling
(SAR), or pulmonary hypertension. The excess mucus production
that defines chronic bronchitis is also thought to be important
in the pathogenesis of acute exacerbations of COPD (Burge
and Wedzicha, 2003). This was previously considered difficult
to reproduce in animal models due to the fact that, in contrast
to humans, the anatomical localization of bronchial glands in
rats and mice are concentrated in the proximal trachea (Churg
et al., 2008). Recently, the mucus secretion was demonstrated in
two rat models (Nie et al., 2012). Authors showed significantly
increased mucus production in epithelium of trachea, bronchi,
and bronchiole in a 6 week cigarette smoke model and in a
chronic bronchitis model with 6 weeks cigarette smoke exposure
combined with a single intratracheal injection of LPS on day 39.
There was also a significant increase in MUC5A protein levels in
broncheoalveolar lavage in both models (Nie et al., 2012).
THE ANATOMICAL MANIFESTATIONS OF COPD
For chronic cigarette smoke exposure studies, many months are
required to model the lung pathology, as acute models do not
have this effect on lung structure and therefore do not allow
the prediction of chronic outcomes. In order to evaluate, for
example, drug efficacies, a chronic exposure most reliably mod-
eling the human disease is essential. Only chronic models can
present the lesions of COPD defined as emphysema, SAR, and
pulmonary hypertension, though still more mildly than in human
COPD (Wright and Churg, 2008; Churg and Wright, 2009). This
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Table 2 | Second hand cigarette smoke exposure modeled in animals.
Species/strain Cigarette
type
Dose and exposure TSP/TPM
(mg/m3)
Nicotine
(mg/m3)
CO (ppm) COPD/emphysema Remarks References
Wistar rat Commercial
Virginia
3/day in 90min, 5
day/week; 3 months
X 1 g/cig 35 Emphysema Nicotine levels correct? Escolar et al.,
1995
A/J KY 1R4F 6h/day, 5 day/week; 6
months
4.1± 0.4 1.011±
0.289
17± 2 Witschi et al.,
1995
Guinea pig Commercial
unfiltered
20/day, 5 day/week; 1–8
weeks
X X 16.3±
4.9% CHG
Emphysema “Whole smoke” Selman et al.,
1996
A/J KY 1R4F 6h/day, 5 day/week; 5
month (harvest 9
months)
78.5±
12.4
13.4 ± 3.3 211± 24 “Whole smoke”;
exposure as in Witschi
et al. (1995)
Witschi et al.,
1997
A/J KY 1R4F 6h/day, 5 day/week; 5
month (harvest 9
months)
0.1± 0.2 3.1 ± 2 113± 23 ”Filtered smoke” Witschi et al.,
1997
Sprague-Dawley rat
hexavalent chromium
i.t.
KY 2R1
humidified
10 cig × 2/day, 3 h rest,
23mm butt; 18 days
120 2.45mg/cig X ”Whole body
environmental”
Balansky et al.,
2000
C57Bl/6, DBA/2, ICR Commercial
Virginia
33ml/min, 3/day, 5
day/week; 7 months
0.9mg/cig X ICR resistant to
emphysema
(anti-oxidants)
“Macrolon cages”;
exposure as in Escolar
et al. (1995)
Cavarra et al.,
2001
Pallid mouse α1
proteinase inhibtor
deficiency
Commercial
Virginia
33ml/min, 3/day, 5
day/week; 4 months
0.9mg/cig X More severe
emphysema
“Macrolon cages”;
exposure as in Escolar
et al. (1995)
Cavarra et al.,
2001
NZ White rabbit Ultratech
Corp
research
cigarettes
6h/day, 48/day, 5
day/week; 10 weeks
24.08±
3.79
339±
74.6 nmol/L
plasma
44.91±
1.81
Sun et al., 2001
SH rat catalytic
anti-oxidant i.t.
(AEOL 10150)
KY 1R4F
humidified
35ml 2 s puff/min,
6 h/day, 3 day/week; 2
day-8 weeks
68.6±
11.7
5.7 ± 2.0 275± 39 Reduced lung injury Smith et al.,
2002
Balb/C a-tocopherol Commercial
filtered
5/day over 60min; 10
weeks
X X X Koul et al.,
2003
ICR Nrf2 KO KY 2R4F 35m3 2s puff × 8,
1min rest, 7 h/day, 7
day/week; 6 months
90 2.45mg/cig 350 More severe
emphysema
Teague chamber;
exposure as in Witschi
et al. (1997)
Rangasamy
et al., 2004
C57Bl/6J Commercial
Virginia
filtered
3/day, 5 day/week; 1–10
months
X 0.9mg/cig X Disseminated
emphysema
“Macrolon cages”;
exposure as in Cavarra
et al. (2001)
Bartalesi et al.,
2005
DBA/2 Commercial
Virginia
filtered
3/day, 5 day/week; 1–10
months
X 0.9mg/cig X Uniform
emphysema
“Macrolon cages”;
exposure as in Cavarra
et al. (2001)
Bartalesi et al.,
2005
C57Bl/CBA and A/J X 6h/day, 5 day/week;
C57Bl/CBA 12 month;
A/J 6 months
250 X 10–12%
CHG
Emphysema (A/J
w/o SAR)
Teague chamber Foronjy et al.,
2005
B6C3F and A/J KY 1R3,
unfiltered
6h/day, 5 day/week; 15
weeks
1. week
100–125,
then 250
X X A/J 51% greater
mean linear
intercept, B6C3F
38%
March et al.,
2005
B6C3F all
trans-retinoic acid
inhalation
KY 1R3,
unfiltered
6h/day, 5 day/week; 32
weeks
1. week
100–125,
then 250
X X No emphysema
reversal
March et al.,
2005
A/J all trans-retinoic
acid i.p. and
inhalation
KY 1R3,
unfiltered
6h/day, 5 day/week; 15
weeks
1. week
100–125,
then 250
X X No emphysema
reversal
March et al.,
2005
C57Bl/6 p.o.
Rofluminlast (PDE4
inhibitor)
Commercial
Virginia
filtered
5 in 20min or 3/day, 5
day/week; 4 h-7 months
X 0.9mg/cig X 100% protected “Macrolon cages”; side
stream presumed;
exposure as in Cavarra
et al. (2001)
Martorana
et al., 2005
(Continued)
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Table 2 | Continued
Species/strain Cigarette
type
Dose and exposure TSP/TPM
(mg/m3)
Nicotine
(mg/m3)
CO (ppm) COPD/emphysema Remarks References
SH rat sEH inhibitor
s.c.
KY 2R4F
humidified
35ml 2 s puff/min,
6 h/day; 3 days
76.4±
16.0
6.8± 0.2 234± 2 Attenuated
inflammation
Smith et al.,
2005
Sprague-Dawley rat
CXCR2 antagonist
SB-332235
KY 2R4F
filtered
2–5 cig/day, 50ml/30 s
over 32min; 24 h 3–4
days (unclear)
X X X Reduced COPD
(time and dose
dependent)
No mention of number of
cigarettes; exposure
period unclear
Stevenson
et al., 2005
C57Bl/6 CCR6 KO KY 2R4F
unfiltered
5 cig × 4/day, 30min
rest, 5 day/week; 4
week-6 months
X X 8.3 ± 1.4
CHG
67% protected
(none against SAR)
Exposure as in D’Hulst
et al. (2005b)
Bracke et al.,
2006
C57Bl/6 TNFR KO KY 2R4F
unfiltered
5 cig × 4/day, 30min
rest, 5 day/week; 3–6
months
X X 8.3 ± 1.4
CHG
100% proteced Side stream presumed;
exposure as in D’Hulst
et al. (2005b)
D’Hulst et al.,
2006
C57Bl/CBA SOD Tg KY 2R4F 2 × 70ml puffs/min,
6 h/day, 5 day/week; 12
months
250 X 10% CHG Prevents
emphysema
Teague chamber Foronjy et al.,
2006
A/J KY 1R3
unfiltered
10–22 week (+39
weeks harvest)
1. week
100, then
250
X X Emphysema
(concentration and
duration dependent)
“Whole body
mainstream”
March et al.,
2006
A/J female KY 1R3
unfiltered
10–22 weeks 1. week
100, then
250
X X Emphysema less
severe
(concentration and
duration dependent)
“Whole body
mainstream”
March et al.,
2006
A/J female p.o.
EGCG anti-oxidant
KY 1R3
unfiltered
16 weeks 1. week
100, then
250
X X Emphysema
(concentration and
duration dependent)
“Whole body
mainstream”
March et al.,
2006
A/J female NAC
anti-oxidant p.o.
KY 2R4F
filtered
10 weeks 1. week
100, then
250
X X Emphysema
(concentration and
duration dependent)
“Whole body
mainstream”
March et al.,
2006
A/J female KY 2R4F
filtered
10 weeks 1. week
100, then
250
X X Emphysema
(concentration and
duration dependent)
“Whole body
mainstream”
March et al.,
2006
C57Bl/6 CCR5 KO KY 2R4F
unfiltered
5 cig × 4/day, 30min
rest, 5 day/week; 4
week-6 months
X X 8.3 ± 1.4
CHG
25% protected
(none against SAR)
Exposure as in D’Hulst
et al. (2005b)
Bracke et al.,
2007
C57Bl/6, A/J, AKR,
CD-1 (ICR), 129Sv
KY 2R4F 35ml 2 s puff/min; 3
days (2 and 24 h harvest)
80: 6 h/day
or 300:
2×
1 h/day
0.85mg/cig 297 (300
TPM); 79.4
(80 TPM)
C57Bl/6 highly
susceptible to
inflammatory and
oxidative response;
A/J, AKR, CD-1 (ICR)
less susceptible;
129Sv resistant
Yao et al., 2008
C57Bl/6, Balb/C, A/J,
129Sv
KY 1R3F 40ml puffs/min; 2, 3, 4,
or 5 cig/day 1h/day; 3
days
481 X X Neutrophilia dose-
and time-dependent
Exposure as in
Stevenson et al. (2005)
Morris et al.,
2008
C57Bl/6 and Balb/C
PKF242-484 MMP
inhibitor p.o. and i.n.
KY 1R3F 40ml puffs/min; 2, 3, 4,
or 5 cig/day 1h/day; 3
days
481 X X Strain-dependent
inhibition of
neutrophil
inflammation
Exposure as in
Stevenson et al. (2005)
Morris et al.,
2008
Hartley guinea pig KY 2R4F 2× 70ml puff/min,
4 h/day, 5 day/week;
1–12 weeks
250 X X Inflammation (4
week), emphysema
(12 week)
Teague chamber Golovatch
et al., 2009
Balb/C KY 1R4F 6 h/day, 5 day/week; 12
weeks
30± 1 4.8± 0.5 X CS augments
inflammatory cell
recruitment in
COPD
Rao et al., 2009
(Continued)
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Table 2 | Continued
Species/strain Cigarette
type
Dose and exposure TSP/TPM
(mg/m3)
Nicotine
(mg/m3)
CO (ppm) COPD/emphysema Remarks References
C57Bl/6J 106
apoptotic thymocytes
i.t.
KY 3R4F 5h; 1 day (harvest and
i.t. d0–5)
25 or 100 X X Reversible and cell
type independent
impaired
efferocytosis in
COPD
Teague chamber Richens et al.,
2009
C57Bl/6J 106
apoptotic thymocytes
i.t.
KY 3R4F 5h/day; 5 day (harvest
+1 and 4 weeks)
100 X X Reversible impaired
efferocytosis in
COPD
Teague chamber Richens et al.,
2009
FVB/N apoptotic
neutrophils
KY 3R4F 5h/day, 5 day/week; 22
week (harvest + 20
weeks)
1. week
100, then
250
X X Non-reversible
impaired
efferocytosis and
termnal bronchiolitis
in COPD
Teague chamber Richens et al.,
2009
ICR oxidant resistant KY 3R4F 5h; 1 day (harvest d0–2) 100 X X No COPD Teague chamber Richens et al.,
2009
C57Bl/6 i.p. MnTBAP KY 3R4F 5h; 1 day (harvest d0–2) 100 X X Anti-oxidant
treatment clears
apoptotic cells and
inhibits RhoA
Teague chamber Richens et al.,
2009
ecSOD Tg KY 3R4F 5h; 1 day (harvest d0–2) 100 X X Anti-oxidant
treatment clears
apoptotic cells and
inhibits RhoA
Teague chamber Richens et al.,
2009
C57Bl/129 TNFR KO KY 3R4F 5h; 1 day (harvest d0–2) 100 X X CS inhibition of
efferocytosis is
TNF-α dependent
Teague chamber Richens et al.,
2009
C57Bl/6J KY 2R4F
humidified
35ml 2 s puff/min, 8
puff/cig, 6 h/day; 3
months
Med 69;
high 131
2.5–6.8
mg/cig
Med 238;
high 394
Inflammatory COPD Teague chamber Woodruff et al.,
2009
A/J KY 2R4F 1. week 125 4h/day, 5
day/week; 20 week
(harvest 20 or 28
weeks)
750 40μg/l 800 Smoking cessation
stops emphysema
progression and
reduces
inflammation
Performed with
maintream and side
stream
Braber et al.,
2010
Balb/C and C57Bl/6 KY 2R4F
filtered
12 cig × 2/day 1. day
20min 2. day 30min,
then 50min, 5
day/week; 4 day-24
weeks
622± 90 377–503.2
ng/ml
cotinin
10–15%
CHG
Inflammation
adaptive
(T regulatory
lymphocytes)
Botelho et al.,
2010
C57Bl/6 P2Y2R KO Commercial
Virginia
filtered
3/day, 5 day/week; 3
day-7 months
X 0.9mg/cig X Protected “Whole smoke”; side
stream presumed;
exposure as in Cavarra
et al. (2001)
Cicko et al.,
2010
Sprague-Dawley rat KY 2R4F 4/day, 5 day/week; 3
day-6 months
27.1±
0.8/cig
2.66 ±
0.12μM
cotinin
42± 4μM
CHG
Emphysema w/o
apoptosis
Marwick et al.,
2010
Balb/C Rag KO with
CS CD3+ T
lymphocyte
KY 3R4F 4h/day, 5 day/week; 6
month (+13 week post
T cell transfer)
150± 15 X 400± 30 Emphysema Teague chamber Motz et al.,
2010a
C57Bl/6J KY 3R4F 4h/day, 5 day/week;
2–24 weeks
150± 15 X X NK cells activate
innate immune
system in COPD
Teague chamber Motz et al.,
2010b
Sprague-Dawley rat
celecoxib i.g.
Commercial
Eighty Eight
Lights
10/day, 2 h/day, 5
day/week; 20 weeks
X X X Reduced
emphysema
Roh et al., 2010
C57Bl/6J SOD3 Tg KY 3R4F 5h/day, 5 day/week; 2–6
months
100 X X Protected Teague chamber Yao et al., 2010
(Continued)
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Table 2 | Continued
Species/strain Cigarette
type
Dose and exposure TSP/TPM
(mg/m3)
Nicotine
(mg/m3)
CO (ppm) COPD/emphysema Remarks References
C57Bl/129 Rtp801 KO KY 2R4F
unfiltered
4/day, 5 h/day; 6 months X 2.45mg/cig X Protected Teague chamber;
exposure as in
Rangasamy et al. (2004)
Yoshida et al.,
2010
A/J KY 2R4F,
whole body
4 h/day, 5 day/week; 20
week (harvest 20 or 28
weeks)
2. week
125, then
750
40μg/l 800 Emphysema “Whole body
mainstream”
Braber et al.,
2011
C57Bl/6 IL-1R1 KO KY 2R4F
unfiltered
12 cig × 2/day 50min, 5
day/week; 4 day-8
weeks
622± 90 377–503.2
ng/ml
cotinin
10–15%
CHG
IL-1R1/IL-1α
dependent
inflammation in
COPD
Exposure as in Botelho
et al. (2010)
Botelho et al.,
2011a
C57Bl/6 IL-1α KO;
Balb/C IL-1α Ab i.p.
KY 2R4F
unfiltered
12 cig × 2/day 50min, 5
day/week; 4 day-8
weeks
622± 90 377–503.2
ng/ml
cotinin
10–15%
CHG
IL-1R1/IL-1α
dependent
inflammation in
COPD
Exposure as in Botelho
et al. (2010)
Botelho et al.,
2011a
C57Bl/6 IL-1β KO;
Balb/C IL-1β Ab i.p.
KY 2R4F
unfiltered
12 cig × 2/day 50min, 5
day/week; 4 day-8
weeks
622± 90 377–503.2
ng/ml
cotinin
10–15%
CHG
IL-1β independent
inflammation in
COPD
Exposure as in Botelho
et al. (2010)
Botelho et al.,
2011a
Balb/C GM-CSF and
GM-CSFR Ab i.p.
KY 2R4F
unfiltered
12 cig × 2/day 1. day
20min 2. day 30min
then 50min; 4 days
622± 90 377–503.2
ng/ml
cotinin
10–15%
CHG
Reduced
inflammatory
response
Exposure as in Botelho
et al. (2010)
Botelho et al.,
2011b
DBA/2J hyaluronan KY 2R4F
filtered
35ml 2 s puff/min,
3 h/day, 5 day/week;
2–10 months
X X X Reduced
emphysema
Teague chamber Cantor et al.,
2011
DBA/2 caspase-3
inhibition
KY 33ml/min, 3/day, 5
day/week; 6 months
90 X 350 Reduced
emphysema
Teague chamber;
exposure as in Cavarra
et al. (2001)
Clauss et al.,
2011
SH rat sEH inhibitor
s.c. or p.o.
KY 3R4F 6 h/day; 3 days 80–90 X X sEH
anti-inflammatory
effect independent
of leukocyte
recruitment
Teague chamber Davis et al.,
2011
C57Bl/6 P2X7
receptor KO
KY 3R4F
unfiltered
250, 500, 750ml/min,
50min × 2/day; 3 days
X X X Inflammation
through P2X7
pathway
Teague chamber Eltom et al.,
2011
C57Bl/129 Smad3 KO KY 2R4F
unfiltered
12 cig × 2/day 50min, 5
day/week; 4 day-8
weeks
622± 90 377–503.2
ng/ml
cotinin
10–15%
CHG
Accelerated
emphysema
Exposure as in Botelho
et al. (2010)
Farkas et al.,
2011
C57Bl/6 and DR4 Tg
M. tuberculosis or
influenza A i.n.
KY 1R4F 2 × 120min/day (2 h
rest) 5 day/week; 6
weeks
80 X X Teague chamber Feng et al.,
2011
C57Bl/CBA KY 2R4F 6 h/day, 5 day/week; 4
week-12 months
X X X Teague chamber;
exposure as in Foronjy
et al. (2005, 2006),
Golovatch et al. (2009)
Geraghty et al.,
2011
Hartley Guinea pig KY 2R4F 6 h/day, 5 day/week; 12
weeks
X X X Teague chamber;
exposure as in Foronjy
et al. (2005, 2006);
Golovatch et al. (2009)
Geraghty et al.,
2011
C57Bl/6 and DBA/2J
adipose stem cell
treatment
KY 3R4F 4, 6 months 90 X 350 Reduced
emphysema
Teague chamber Schweitzer
et al., 2011
Balb/C AZD9668 NE
inhibitor p.o.
KY 1R3F 12 cig 2 × 50min/day; 4
days
X X X Reduced
emphysema and
SAR
Stevens et al.,
2011
(Continued)
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Table 2 | Continued
Species/strain Cigarette
type
Dose and exposure TSP/TPM
(mg/m3)
Nicotine
(mg/m3)
CO (ppm) COPD/emphysema Remarks References
C57Bl/6 IL-1R1 and
IL-1α KO
KY 3R4F
unfiltered
12 cig × 2/day 50min, 5
day/week; 4 day-8
weeks
622± 90 377–503.2
ng/ml
cotinin
10–15%
CHG
DC accumulation
and activation is
IL-1R1/IL-1α
dependent
Exposure as in Botelho
et al. (2010)
Botelho et al.,
2012
C57Bl/6 TLR4 KO KY 3R4F
unfiltered
12 cig × 2/day 50min, 5
day/week; 4 day-8
weeks
622±
90μg/l
TPM
377–503.2
ng/ml
cotinin
10–15%
CHG
DC accumulation
and activation is
TLR4-independent
Exposure as in Botelho
et al. (2010)
Botelho et al.,
2012
Balb/C IL-1α Ab i.p. KY 3R4F
unfiltered
12 cig × 2/day 50min; 4
days
622±
90μg/l
TPM
377–503.2
ng/ml
cotinin
10–15%
CHG
DC accumulation
and activation is
IL-1α dependent
Exposure as in Botelho
et al. (2010)
Botelho et al.,
2012
Balb/C IL-1β Ab i.p. KY 3R4F
unfiltered
12 cig × 2/day 50min; 4
days
622±
90μg/l
TPM
377–503.2
ng/ml
cotinin
10–15%
CHG
DC accumulation
and activation is
IL-1β-independent
Exposure as in Botelho
et al. (2010)
Botelho et al.,
2012
SH rat KY 3R4F 35ml 2 s puff, 6 h/day, 3
day/week; 3 day-12
weeks
80–90 X X Leukocytes from
bronchial circulation
in COPD
Nicotine and CO levels
measured daily, but not
listed; Teague chamber
Davis et al.,
2012
Sprague-Dawley rat Ye Shu
unfiltered
1. day 3/h each; 2. day:
7/h each; 3–5. day:
12/3min; 6. day-end:
12/h; 4–6 weeks
70–110 1.2mg/cig 310–380 COPD Chamber uniquely
described; side stream
presumed
Nie et al., 2012
SH rat sEH inhibitor
and Rolipram p.o.
KY 3R4F 35ml 2 s puff/min,
6 h/day, 3 day/week; 4
weeks
80–90 X X Reduced
emphysema
Teague chamber Wang et al.,
2012
Mouse Apo-E KO C.
pneumoniae
KY 3R4F 35ml 2 s puff/min,
6 h/day, 5 day/week; 8
weeks
X X X Enhanced
artherosclerosis
Zhao et al.,
2012
Balb/C and C57Bl/6 KY 3R4F 4h/day, 5 day/week; 6
months
150± 15 X 400± 30 Emphysema CD4+
and CD8+ T
lymphocyte
dependent
(Ag-specific
response)
Teague chamber Eppert et al.,
2013
Sprague-Dawley rat KY 1R3F 5 cig/9min 6h/day; 2–4
months
100–120
μg/m3
X X Emphysema Teague chamber Kratzer et al.,
2013
C57Bl/6 IKK-2 KO KY 3R4F
unfiltered
500ml/min, 50min;
3–14 days
X X X Unaltered
inflammation
Teague
chamber;exposure as in
Eltom et al. (2011)
Rastrick et al.,
2013
CHG, carboxyhemoglobin; SAR, small airway remodeling. Cigarette brand names are in bold.
is especially important when noting that, because rodents develop
a mild form of COPD, drug tests should be performed as late as
possible to mimic a treatment versus a prophylaxis (Churg et al.,
2011).
EMPHYSEMA
The pathogenesis of emphysema is studied by inducing the dis-
ease with various methods not necessarily restricted to cigarette
smoke. The protease/anti-protease hypothesis has been the main
focus in elucidating the cause of emphysema. In addition, oxida-
tive stress has been shown to cause lung cell apoptosis in an
emphysema model using a vascular endothelial growth factor
(VEGF) receptor blocker (Kasahara et al., 2000; Tuder et al.,
2003). Cigarette smoke induces both oxidative stress and the
infiltration of inflammatory cells, which release proteases that
overwhelm the anti-proteolytic defenses. Inflammatory cell and
consequently endothelial cell proteases lead to the breakdown of
pulmonary matrix and alveolar walls following particle inhala-
tion, creating airspace enlargement and minimizing surface area
for gas exchange (March et al., 2000). This protease theory is
based on the 1963 finding that patients deficient in α-1 antit-
rypsin, a major neutrophil elastase inhibitor, have accelerated
emphysema development (Laurell and Eriksson, 1963). The capa-
bility of proteases to cause emphysema was then verified by instill-
ing them intratracheally (Gross et al., 1965; Janoff et al., 1977;
Snider et al., 1984). Protease inhibition has since been tested in
the animal model with varying efficacies, depending on the pro-
tease depleted. Serine proteases from neutrophils (59% protection
in neutrophil elastase deficient mice) (Shapiro et al., 2003) as well
as macrophage metalloproteases (Hautamaki et al., 1997) have
been consideredmost important in a cigarette smoke induced dis-
ease model, but the more broad application of anti-inflammatory
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Table 3 | Animal studies where the exposure (mainstream or second hand smoke) is not known.
Species/strain Cigarette
type
Dose and exposure TSP/TPM
(mg/m3)
Nicotine
(mg/m3)
CO (ppm) COPD/Emphysema Remarks References
C57Bl/6J A1AT low
pallid mouse
KY 2R1
unfiltered
2–6 months X X 10–12%
CHG
Emphysema No exposure method Takubo et al.,
2002
C57Bl/6, NZW, A/J,
SJ/L, AKR/J
KY 2R1
unfiltered
2/day, 5 day/week; 6
months
X X 10–12%
CHG
Strain-dependent
susceptibility to
emphysema
No exposure method Guerassimov
et al., 2004
C57Bl/6 and Balb/C
INF-g Tg
X 6 months X X X Enhanced
emphysema
No exposure method Ma et al., 2005
C57Bl/6 CCR5 KO X 6 months X X X 100% protected No exposure method Ma et al., 2005
C57Bl/6 KY 2R1 4/day once or 3/day, 5
day/week; 2 h-6 months
X X X SAR No exposure method Churg et al.,
2006
C57Bl/6 A1AT i.p. KY 2R1 4 in 2h X X X No emphysema No exposure method Churg et al.,
2007b
C57Bl/6 KY 2R1 20ml × 2 cig/day
15min, 6 day/week; 6
months
X X X Emphysema No exposure method Adair-Kirk et al.,
2008
CHG, carboxyhemoglobin; SAR, small airway remodeling. Cigarette brand names are in bold.
Table 4 | Cigarette types used for the summarized experiments.
Cigarette brand Type Year TSP/TPM (mg/cig) Nicotine (mg/cig) CO (mg/cig) References
Kentucky 1R3 1974 27.1 and 23.6 1.46 and 1.23 17.1 and 14.7 Davis et al., 1983
Kentucky 1R3F 1974 18.1 1.16 17.2 Davis et al., 1983
Kentucky 1R4F 1983 10.3* 0.8* 11.6* Davis et al., 1983
Kentucky 2R1 1974 14.6 and 38.8 2.45 and 2.19 25.1 and 22.2 Davis et al., 1983
Kentucky 2R1F 1974 28.6 1.74 22 Davis et al., 1983
Kentucky 2R4F 2001 11.7 0.9 13 Roemer et al., 2012
Kentucky 3R4F 2008 11 0.7 12 Roemer et al., 2012
Virginia F 0.9 35 (Escolar et al., 1995) Escolar et al., 1995; Cavarra et al., 2001;
Bartalesi et al., 2005; Martorana et al.,
2005; Cicko et al., 2010
Seven Star UF 1.88% Gomita et al., 1990
Long Peace F 1.9–2 Suemaru et al., 1992; Tanaka et al., 2004
Ultratech Corp n.a. 24.08 ± 3.79 339 ± 74.6nmol/L 44.91 ± 1.81 Sun et al., 2001
Ye Shu UF 70–110 1.2 310–380 Nie et al., 2012
Marlboro 100F 971 ± 98.3 in 5% 1 12 Suzuki et al., 2009; Shan et al., 2012
Eighty Eight Lights n.a. 0.72 9 Lee et al., 2005; Roh et al., 2010
Arda-Bulgartabac F 533 1.6mg/cig Balansky et al., 2000
Canada Tobacco UF 1.1 11 Wright and Churg, 1990
F, filtered (KY 30mm butt); UF, unfiltered; KY values, 23 and 30mm butt; *, 35mm butt.
interventions has proven useful in smoked rodents as well (Churg
et al., 2008). This is especially of interest, as sampling of human
COPD specimens noted T lymphocytes in alveolar destruction
and airflow obstruction, though smoking history was not assessed
in the patient population (Hogg et al., 2004). This has shed
light on the participation of auto-immunity contributing to the
overall pathogenesis of emphysema through anti-endothelial cell
antibodies and pathogenic CD4+ T lymphocytes (Taraseviciene-
Stewart et al., 2005). Because emphysema was initially believed
to occur through the same mechanism as SAR and to be the
underlying cause of pulmonary hypertension, both in COPD as
well as following cigarette smoke exposure, many studies have
focused only on the emphysematous pathology, especially on
the proteolytic aspect, neglecting further complex contributing
factors.
SMALL AIRWAY REMODELING (SAR)
Emphysema is not the only manifestation of cigarette smoke
induced COPD. SAR is also a major contributor to the dis-
ease as it limits airflow (Hogg et al., 2004) and is character-
ized by continuous repair for the duration of smoke expo-
sure (Churg and Wright, 2009). While emphysema is the
breakdown of extracellular matrix in the lung parenchyma,
SAR pathogenesis involves a fibrotic process leading to airway
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narrowing due to airway wall thickening. Therefore, it is not
surprising that SAR appears to develop through a mecha-
nism independent of the one that drives emphysema. This
correlates well with the fact that methods for emphysema pre-
vention cannot be uniformly applied to treat SAR. Only TNF-
α and IL-1 receptor knockouts (Churg et al., 2009b) as well
as mice treated with an MMP-9/MMP-12 inhibitor (Churg
et al., 2007a) were protected against the development of both
emphysema and SAR when exposed to cigarette smoke, while
other interventions such as chemokine receptor 5 (CCR5)
(Bracke et al., 2007) and CCR6 (Bracke et al., 2006) knock-
outs are merely protected from emphysema following cigarette
smoke.
PULMONARY HYPERTENSION
COPD morbidity and mortality are significantly increased by the
not uncommon occurrence of pulmonary hypertension associ-
ated with cigarette smoke (Chaouat et al., 2008; Elwing andPanos,
2008), which correlates with a poor prognosis (Weitzenblum
et al., 1981). Originally, it was believed that the increase in
pulmonary artery pressure is secondary to the lung pathology
associated with COPD, as a result of hypoxia, emphysema, and
loss of the vascular bed (Wright et al., 2005). With the realiza-
tion that smoke and its mediators effect vasculature to induce
remodeling, and that pulmonary hypertension is an early symp-
tom that manifests long before airflow obstruction, emphysema,
and SAR, the independent mechanism became evident (Wright
et al., 2005). It has recently been shown that inducible nitric
oxide synthase (iNOS) is important in the development of pul-
monary hypertension following cigarette smoke exposure (Gielis
et al., 2011; Kratzer et al., 2013). Mice lacking iNOS or treated
with an iNOS inhibitor are protected against the cigarette smoke
induced development of emphysema and pulmonary hyperten-
sion (Nathan, 2011; Seimetz et al., 2011). Both prostacyclin and
endothelial NOS are protective against pulmonary hypertension
induced by hypoxia, while endothelin-1 and VEGF contribute to
the pathogenesis (Wright et al., 2004, 2005; Voelkel, 2008; Wright
and Churg, 2008). The oxidative damage to the vasculature results
from reactive nitrogen species that are not of endothelial source,
but more likely contained in the cigarette smoke itself (Wright
et al., 2012). The result is altered vasoconstriction and vasodi-
lation as well as vascular cell proliferation leading to the patho-
logical thickening of vessels. In the intima, elastin and collagen
are deposited, while smooth muscle cells proliferate (muscular-
ization), and adventitia harbors increased numbers of CD8+ T
lymphocytes (Wright et al., 1983, 1992; Barbera et al., 2003).
Smoking is not only the main risk factor for COPD and
pulmonary hypertension, but also for coronary artery disease
summarized in a recent review (Ghoorah et al., 2012).
THE PROTEOLYTIC AND INFLAMMATORY RESPONSE
IN COPD
COPD, like asthma, is characterized by chronic and abnor-
mal inflammation of the distal airways resulting in airflow
limitation, but differs from asthma in that it is progres-
sive and largely irreversible. This chronic disease encompasses
bronchiolitis and fibrosis with obstruction of small airways,
vascular remodeling leading to pulmonary hypertension, destruc-
tion of lung parenchyma with loss of the alveolar wall and
subsequent airspace enlargement defined as emphysema, as well
as loss of lung elasticity. The underlying mechanisms involve
protease/anti-protease imbalance following inflammation, with
subsequent proteolytic matrix destruction (Churg et al., 2008),
oxidant damage that leads to apoptosis of resident lung structure
cells (Yoshida and Tuder, 2007; Churg et al., 2011). accelerated
aging (Csiszar et al., 2009), a failure to repair, and the con-
tribution of autoimmunity (Taraseviciene-Stewart et al., 2006;
Maeno et al., 2007; Stampfli and Anderson, 2009). The most
prominent and frequent etiology of COPD remains cigarette
smoke and its onset is mid-life. For COPD, the inflammatory
response is slowly progressive and leads to the actual destruc-
tion of lung parenchyma where alveolar walls disappear and the
distal airspaces become pathologically and permanently enlarged,
resulting in emphysema (Barnes, 2004). The contributing inflam-
matory cells in COPD are neutrophilic granulocytes, alveolar
macrophages, and CD8+ T lymphocytes (Taraseviciene-Stewart
and Voelkel, 2008; Stampfli and Anderson, 2009). The accu-
mulation of both T and B lymphocytes following apoptosis of
resident lung cells has been described to create follicles within
the lung parenchyma, adjacent to airways, in COPD (Hogg et al.,
2004; Taraseviciene-Stewart et al., 2006). In a rat model, neu-
trophil depletion did not prevent smoke induced emphysema,
while treatment with anti-monocyte/macrophage antibody did.
These findings implicate macrophages rather than neutrophils as
the critical pathogenic factor in cigarette smoke induced emphy-
sema (Ofulue and Ko, 1999). Macrophages are known to secrete
the cytokines interleukin 8 (IL-8) and tumor necrosis factor
alpha (TNF-α) as well as leukotriene B4 (LTB4), all found to be
increased in COPD patients (Keatings et al., 1996). Additionally,
macrophages also generate reactive oxygen species (ROS), mono-
cyte chemotactic protein 1 (MCP-1) and elastolytic enzymes such
as matrix metalloproteinase (MMP)-2, MMP-9, MMP-12, and
cathepsins K, L, and S thus contributing to the lung destruction
(Barnes et al., 2003).
Neutrophils are found to be increased in bronchial biopsies
and sputum of patients during COPD, correlating with severity
(Keatings et al., 1996; Di Stefano et al., 1998; Pesci et al., 1998;
Retamales et al., 2001). Neutrophils apparently contribute to the
disease pathogenesis by secreting serine proteases (neutrophil
elastase, cathepsin G, proteinase) and metalloelastases MMP-8
and MMP-9 (Barnes et al., 2003).
The major pathogenetic factor of neutrophil and macrophage
accumulation in emphysema is their secretion of proteases and
inflammatory mediators. Cleaved fragments of elastin, collagen,
and fibronectin are believed to possibly act as auto-antibodies,
which would explain the accumulation of T and B lympho-
cytes in COPD patients (Hogg et al., 2004; Taraseviciene-Stewart
and Voelkel, 2008), It has been shown that antibodies against
endothelial cells correlate with alveolar septal cell apoptosis as
well as the activation of MMP-2 and MMP-9, thereby initiat-
ing the proteolytic cascade and inducing emphysema indepen-
dent of cigarette smoke (Taraseviciene-Stewart et al., 2005). This
specific mechanism of anti-endothelial cell auto-immunity is
dependent on CD4+ T lymphocytes believed to be pathogenic
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(Voelkel and Taraseviciene-Stewart, 2005; Taraseviciene-Stewart
et al., 2007). Anti-endothelial cell antibodies were also detected
in a rat model of cigarette induced emphysema (Taraseviciene-
Stewart, unpublished observation).
GENETIC PREDISPOSITIONS FOR COPD DEVELOPMENT
Interestingly, only 15–20% of smokers are susceptible to devel-
oping COPD, underlining the contribution of genetic factors
(Fletcher and Peto, 1977). This susceptibility is mirrored in
the animal model, where the development of cigarette smoke
induced emphysema is strain-dependent (Guerassimov et al.,
2004; Bartalesi et al., 2005). To this date, though, the only human
genetic predisposition identified is the rare hereditary deficiency
in α-1 antitrypsin (Laurell and Eriksson, 1963). Transgenic mice
over-expressing genes of interest or knockout mice lacking a spe-
cific gene are exposed to mainstream or SHS elucidating how a
specific gene modifies the pathogenesis of this disease. Though
mice are so small that the assessment of disease progression
and COPD symptoms is hindered, the application of transgenic
and knockout mice to define the effects of a gene insertion or
expression increase as well as that of a gene deletion, can answer
many questions. Additionally, 80% of the mouse genome con-
tains genes that have direct orthologues in the human genome
and less than 300 genes (1%) are unique to the murine species
(Waterston et al., 2002; Pennacchio, 2003). Interestingly, 89–90%
of rat genes contain single orthologues in the human genome and
76% of well-characterized human disease genes are found in the
rat genome (Gibbs et al., 2004). Both rats (Pauwels et al., 1985;
Martin et al., 1992) and mice (Guerassimov et al., 2004; Bartalesi
et al., 2005) have strain-dependent susceptibilities to excessive air-
way inflammation and smoke-induced emphysema, respectively,
just as humans have genetic susceptibility to developing COPD.
PREVENTATIVE THERAPIES
The most prominent interventions studied for COPD are anti-
proteolytic, anti-inflammatory, as well as anti-oxidant and are
directed against the development of emphysema, often not even
being tested for SAR or pulmonary hypertension efficacies (Churg
et al., 2011). Proteases are released by both accumulating inflam-
matory as well as resident cells, causing matrix destruction in the
alveolar wall and therefore emphysema. This hypothesis is sum-
marized in the term protease/anti-protease imbalance, because
both an excessive protease release as well as a hindered anti-
protease activity is necessary to contribute to the pathogene-
sis. The inhibition of various proteases during cigarette smoke
exposure has been tested: serine proteases (neutrophil elastase)
(Cavarra et al., 2001; Takubo et al., 2002; Wright et al., 2002;
Churg et al., 2003b; Shapiro et al., 2003; Pemberton et al., 2006),
different metalloproteases (MMP-9 and MMP-12) (Hautamaki
et al., 1997; Selman et al., 2003; Mahadeva and Shapiro, 2005;
Pemberton et al., 2005; Churg et al., 2007a), and cysteine pro-
teases (cathepsins B and S) (Kang et al., 2007). The preventative
success depends on the specific protease inhibited.
The immune reaction to chronic smoke exposure has been
investigated by blocking certain inflammatory responses using
knockout mice or simply applying an anti-inflammatory treat-
ment. Both anti-TNF-α receptor (Churg et al., 2004; D’Hulst
et al., 2006) and anti-PDE4 (Rofluminlast) (Martorana et al.,
2005) therapies are protective anti-inflammatory measures in
the animal model, though these results could not be as success-
fully reproduced for the chronic human disease (Barnes, 2007).
Significant protection against SHS induced emphysema in the
animal model was also achieved using a hyaluronan aerosol
(Cantor et al., 2005) and by blocking interferon γ (INF-γ) or
CCR5 (Ma et al., 2005; Bracke et al., 2007) or CCR6 (Bracke et al.,
2006), After it was shown that SCID (severe combined immuno-
deficient) and Rag (recombinase activating gene) knockout mice,
which both lack functional T and B lymphocytes, are not pro-
tected from mainstream smoke induced emphysema (D’Hulst
et al., 2005a), CD4+ and CD8+ T lymphocyte-deficient mice
were tested individually. While CD4+ T lymphocyte-defecient
mice are not at all protected, CD8+ T lymphocyte-deficient mice
are 100% protected against emphysema following mainstream
exposure (Maeno et al., 2007). Toll-like receptor 4 (TLR4) knock-
out mice were also not protected (Maes et al., 2006). Statins,
however, have proven to be protective against cigarette smoke
induced emphysema in rats (Lee et al., 2005) and appear to
be promising therapy in humans as well (Soyseth et al., 2007).
Simvastatin additionally is effective against pulmonary hyper-
tension, but unfortunately does not prevent SAR (Wright et al.,
2011), unless administered before disease onset (Lee et al., 2005;
Ou et al., 2009).
ROS are both contained in cigarette smoke and released by the
resultant infiltrating cells, such as neutrophils and macrophages
(Pryor and Stone, 1993; Rahman and MacNee, 1996; MacNee,
2001). This, again, leads to an imbalance, that of oxidants and
anti-oxidants, so that the lung is exposed to oxidative stress
(Petrache et al., 2006). Susceptibility to oxidative stress is, like
the genetic predisposition for cigarette smoke induced emphy-
sema, specific to a certain strain of mice (Cavarra et al., 2001;
Bartalesi et al., 2005). Oxidant sensitive mice show less anti-
oxidant capacity when exposed to cigarette smoke, developing
emphysema. This effect can be reduced when applying an oral
anti-oxidant (Koul et al., 2003), while elimination of the redox
sensitive transcription gene Nuclear factor 2 (Nrf2) enhanced
the cigarette smoke induced oxidative stress and emphysema
in the otherwise resistant ICR mouse strain (Rangasamy et al.,
2004).
Concisely, emphysema induced by cigarette smoke is a
multi-factorial disease and therapeutic approaches should be
undertaken to repair the lung structure by preventing marix
degradation by reducing proteases, inflammation, oxidative
stress, cell death, and/or autoimmune-mediated destruction.
STUDY PARAMETERS THUS FAR
Here we have compiled 114 publications containing 155
studies addressing cigarette smoke exposure in the animal
model. Approximately half of the studies (71 experiments) are
mainstream exposure (Table 1). Side stream smoke exposures
(Table 2) make up 77 experiments of the studies listed herein and
a small portion (7 studies) is unclear about the exposure method
utilized (Table 3). Of the studies listed here, a large portion (115
studies) utilizes quite a strain diversity of mice (C57Bl/6, DBA/2,
Balb/C, A/J, ICR, FVB, or a strain not described), although
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C57Bl/6 mice are dominant (83 experiments). C57Bl/6 mice are
a common strain for knockout studies and generally a popular
model for cigarette smoke induced emphysema (Takubo et al.,
2002; Guerassimov et al., 2004; Bartalesi et al., 2005; Yao et al.,
2008; Botelho et al., 2010) due to their deficiency in anti-elastase
(Gardi et al., 1994; Cavarra et al., 2001). Balb/C mice with higher
levels of the cytokine granulocyte-macrophage colony stimulat-
ing factor (GM-CSF) (Morris et al., 2008; Botelho et al., 2010,
2011b) and the oxidant sensitive strain DBA/2 (Cavarra et al.,
2001; Bartalesi et al., 2005) have also been shown to have severe
emphysema following cigarette smoke exposure. ICR mice are
considered oxidant resistant and are of interest when attempting
to induce disease (Cavarra et al., 2001; Rangasamy et al., 2004;
Hodge-Bell et al., 2007; Yao et al., 2008). A/J express less severe
pulmonary complications (Guerassimov et al., 2004; Yao et al.,
2008; Braber et al., 2010) and have found use in drug tests, but
have been used as a model for chronic cigarette smoke exposure
as well (Foronjy et al., 2005; March et al., 2005, 2006). Apart from
mice, one study addresses rabbits, 15 utilize guinea pigs (either
Hartley strain or not named), while 24 studies gravitate toward
using rats. These are almost exclusively Sprague-Dawley, while
spontaneously hypertensive rats (SH) as well as Wistar Kyoto are
also popular.
Originally, only studies from 1997 onwards were added to
Tables 1–3, but with such consistency of certain researchers to
repeatedly reference earlier publications, the original publish-
ers of certain exposure procedures were included as far back as
1974. A number of authors stumble when it comes to actually
stating clearly whether their exposure method was mainstream
or side stream. This is most likely due to the assumption that
this would be known according to the exposure system more
or less detailed in the Materials and Methods section or merely
mentioned in the abstract. The Materials and Methods section,
though, frequently references a publication that, in turn, refer-
ences the original design. Such a basic fact as mainstream or
side stream exposure must be pointed out, as must the fact that
there was a cigarette smoke exposure at all, also something that
can be quite hidden in a less specific manuscript. Fortunately,
many publications do announce a head/nose only or a whole body
exposure in the Materials and Methods section, if mainstream
or side stream (environmental or second hand) has not already
been mentioned in the abstract or introduction. There are some
that allow you to look up their chamber of choice, although this
leads to lengthy product guidelines tediously researched online
(i.e., the long outdated Hamburg II chamber). There are only a
few groups that generally use the same procedure and one can
at least assume that they are utilizing the same method, sim-
ply using their latest publication as the current reference (which
then must be referenced back to the original procedure). It is a
relatively safe assumption that the method always remains main-
stream or side stream within the same research group, unless
otherwise noted, but it is left for the reader to assume, nonethe-
less. In this summary, only two research groups resort to this form
of documentation.
Seven publications segregated in Table 3 leave it completely
unknown what exposure they have used, and one uses a
“whole body mainstream” exposure, apparently employing a high
concentration of cigarette particulates into a chamber to mimic
mainstream smoking (Braber et al., 2011), but that is, again, left
to be assumed. Generally, one can still assess the exposure method
in most cases, it becomes less clear at the level of nicotine, carbon
monoxide, and particulate levels. Some researches are very dili-
gent here, while others may not have measured these parameters
and therefore do not address them. There is also somewhat vari-
ability to whether nicotine and TSP/TPM are measured as mg/m3
or μg/l (which can easily be calculated to mg/m3). Some quote
mg/cig for the nicotine levels (Pittilo et al., 1982, 1990; Suemaru
et al., 1992; Escolar et al., 1995; Wright and Sun, 1999; Wright
et al., 1999; Balansky et al., 2000; Cavarra et al., 2001; Wright and
Churg, 2002; Rangasamy et al., 2004; Tanaka et al., 2004; Bartalesi
et al., 2005; Martorana et al., 2005; Yao et al., 2008; Woodruff
et al., 2009; Cicko et al., 2010; Miller et al., 2010; Yoshida et al.,
2010; Nie et al., 2012; Nemmar et al., 2013), meaning this was
likely looked up through the manufacturer. The same is true for
carbon monoxide, which is either measured in ppm or percent-
age of carboxyhemoglobin in the serum. It is clear that the vast
majority of studies has, at bare minimum, one of these parame-
ters missing, as only 24 (15.5%) exemplary studies listed all three.
Usually, the levels named are an average kept during the entire
exposure period, which is of importance when considering SHS
exposure. The TSP/TPM levels in SHS exposures is as low as
24mg/m3 using a unique rabbit model (Sun et al., 2001), but as
high as 250mg/m3 in standard Teague chamber mouse models
using Kentucky reference cigarettes (Foronjy et al., 2005, 2006;
Golovatch et al., 2009; Richens et al., 2009). The Stampfli lab
(Botelho et al., 2010, 2011a,b, 2012; Farkas et al., 2011) and one
other group (Braber et al., 2010) go beyond 700mg/m3 for their
mouse models that do not utilize the Teague chamber.
There is still diversity in the use of cigarettes (Table 4), despite
the fact that reference cigarettes, specifically designed for this
type of research, have been available for approximately four
decades now. The vast majority of studies (111 studies mak-
ing up 71.6%) do use the reference cigarettes provided by the
University of Kentucky’s Tobacco Research and Development
Center (formerly the Tobacco and Health Research Institute).
Two groups have listed all necessary parameters with the unique
cigarettes (Ultratech Corp and Ye Shu) they have chosen (Sun
et al., 2001; Nie et al., 2012). Unfortunately, it appears that com-
mercial Virginia cigarettes are popular, without specifying which
kind, though apparently generally a type with 0.9mg nicotine
per cigarette, except for one study that claims to use Virginia
cigarettes with 1 g nicotine per cigarette, presumably a typo
(Escolar et al., 1995). A total of 17 studies do not list the cigarettes
used (either commercial unfiltered, simply unfiltered, or no ref-
erence at all), while five publications compromising eight studies
do opt for Kentucky reference cigarettes, but then neglected to
list which kind, let alone the parameters (Hautamaki et al., 1997;
Shapiro et al., 2003; Maeno et al., 2007; Nakanishi et al., 2009;
Clauss et al., 2011).
Other cigarette brands listed in Tables 1–3 stated only some
or none of the parameters for TSP/TPM, nicotine, and car-
bon monoxide levels. The eight remaining brands of cigarettes
are Marlboro 100 and Marlboro red (for Marlboro Medium
sort, the nicotine level is 1mg/cig and carbon monoxide is
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12mg/cig), Long Peace and Seven Star (Japan), Eighty Eight
Lights (South Korea), Arda-Bulgartabac (Bulgaria), Canada
Tobacco, and Virginia brand. For these cigarettes, the parameters
could not be found to supplement the information available in
the original publications themselves, as the actual type of cigarette
was not stated in any one of them. Therefore, data regarding ref-
erence cigarettes used in the studies summarized here have been
left incomplete in Table 4.
Kentucky reference cigarettes, on the other hand, are very well
documented, but sometimes it is unclear in a publication whether
a mix of two types was used for smoke exposure. At times, the fil-
tered version (named with an “F” by the manufacturer) is used,
but the filter is removed. There are also those who list using
2R4, which presumably means that the filter was removed for the
study. The first line of reference cigarettes from the University of
Kentucky were from 1974 and included 1R3, 1R3F, and 2R1, of
which the filtered kind (1R3F) had 30mm butts and the unfil-
tered cigarettes (1R3 and 2R1) could be purchased with either
23 or 30mm butt lengths. In 1983, the new generation of refer-
ence cigarettes was 1R4F, only available in a 35mm butt length.
In 2001, the next generation, named 2R4F, was launched and as
of 2008 3R4F has been produced. Studies presumably reflect the
reference cigarette of the time and the well-documented levels of
Kentucky reference cigarettes can be found in their entirety in
Table 4.
COMPARING MAINSTREAM AND SECOND HAND
EXPOSURES
Although parameters appear to rarely be listed to the extent they
should be, we have attempted to compare the direct exposure
of smoke in these animal studies to those of animals exposed
via a whole body method, mimicking SHS. One must remem-
ber that while mainstream smoke is inhaled into the lungs from
the cigarette directly, SHS is the inhalation of suspended particles
from the smoker’s exhale and the burning end of the cigarette,
thereby concentrations of particles and individual components
are not necessarily reduced, as one would hope. What becomes
clear is, that SHS exposure does indeed lead to emphysema and
other COPD symptoms in animal models. A multitude of studies
elucidate this fact and they are summarized in Table 2, which also
highlights what effects (whether emphysema, SAR, or pulmonary
hypertension) were assessed.
Studies to unravel the pathogenic mechanisms of cigarette
smoke exposure were undertaken in the knockout models, where
the effect can easily be seen based on only one factor. The central
role of TNF-α has been documented for both exposure appli-
cations. This was made evident by inhibition of TNF-α using
a receptor knockout model (TNFR KO), which attenuated the
development of emphysema by 71–83% and of SAR by 100% in
mainstream cigarette smoke exposure (Churg et al., 2002a, 2004,
2009b). TNFRKOwere 100% protected against emphysema using
side stream smoke (D’Hulst et al., 2006). Additionally, inhibition
of efferocytosis is TNF-α dependent in the side stream knockout
model (Richens et al., 2009).
C–C CCR5 knockout mice were 100% protected against
emphysema in an exposure method that was not defined, where
INF-γ over-expression enhanced emphysema (Ma et al., 2005).
In a side stream exposure study (Bracke et al., 2007), the effect
of CCR5 knockout was only protective to 25%, whereas CCR6
knockout was more effective with 67% protection against emphy-
sema (Bracke et al., 2006). It is possible that the same manip-
ulation would be more protective in a mainstream versus a
second hand exposure, although the exposure in the first study,
which assessed a number of pathways leading to apoptosis, is not
known.
Another well-documented knockout model for the mecha-
nism of smoke induced pathology is that of macrophage elastases,
specifically MMP-12 (Hautamaki et al., 1997; Churg et al., 2002a,
2003a; Shapiro et al., 2003) and MMP-9 (Atkinson et al., 2010).
The elastinolytic activity central to matrix breakdown and alve-
olar enlargement had already been attributed to macrophages
(Ofulue et al., 1998; Ofulue and Ko, 1999) and these two enzymes
were pinpointed via inhibition (Churg et al., 2007a). Here, MMP-
12 (also termed macrophage metalloelastase MME) has been
identified to be of foremost importance in lung destruction,
since MMP-12 knockout mice are resistant to smoke induced
emphysema, while emphysema can occur independent of MMP-
9 (Atkinson et al., 2010). Mice deficient in monocytes and
macrophages do not develop enlarged airspaces upon cigarette
smoke exposure, while those deficient in polymorphonuclear cells
(PMN) do (Ofulue et al., 1998; Ofulue and Ko, 1999; Dhami et al.,
2000). Unfortunately, all studies regarding MMP contributions,
which are considerable, have solely been tested in the mainstream
smoke model.
The neutrophil-derived serine elastase has been implicated in
both a mainstream and a side stream exposure model (Dhami
et al., 2000). In a direct smoke exposure model, the neutrophil
elastase knockout mouse is 59% protected against emphysema
development (Shapiro et al., 2003), while specific neutrophil elas-
tase inhibitors are similarly protective in the guinea pig model
(Wright et al., 2002; Stevens et al., 2011). In a SHS exposure model
of the mouse, one group (Stevens et al., 2011) was also able to
detect a marked decrease in SAR development in both their main-
stream and side stream exposure models upon treatment with
neutrophil elastase inhibitor AZD9668.
The only thus far defined true genetic factor described in
man predisposing to COPD is α-1 antitrypsin deficiency. This
deficiency leads to accelerated development of emphysema fol-
lowing cigarette smoke exposure. Although the importance of
α-1 antitrypsin has been documented in the animal model of
direct cigarette smoke (Dhami et al., 2000; Churg et al., 2003b),
there are two studies where it is not clear whether an indirect
exposure was utilized (Takubo et al., 2002; Churg et al., 2007b).
Nevertheless, α-1 antitrypsin is indeed protective against emphy-
sema in a dose-dependent manner, indicating that this is likely
also true for indirect cigarette smoke exposure (Dhami et al.,
2000; Churg et al., 2003b).
In addition to genetic manipulations elucidating molec-
ular mechanisms of cigarette smoke pathogenesis, there are
also models for drug testing, more specific to an intervention
protocol. These go beyond simply attenuating the proteolytic
breakdown via inhibition of just one protease and encom-
pass mainly statins and anti-oxidants. Simvastatin, as mentioned
above, has a protective effect against emphysema and pulmonary
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hypertension, but not SAR, and has been tested in both the
guinea pig (Wright et al., 2011) and the rat (Lee et al., 2005),
but only using a mainstream exposure method. Therefore, a
homologous mechanism for side stream smoke is yet to be
described.
Beyond being influenced by mouse strain (Guerassimov et al.,
2004; Bartalesi et al., 2005; Foronjy et al., 2005), emphysema
development is also dependent on the airspace content of anti-
oxidants. This was demonstrated by comparing bronchoalveolar
lavage (BAL) levels of endogenous anti-oxidants from the oxi-
dant resistant mouse strain ICR with that from other strains
(Cavarra et al., 2001; Richens et al., 2009). Successful anti-
oxidant therapy is seen for mainstream (March et al., 2006;
Suzuki et al., 2009; Churg et al., 2012) and side stream expo-
sure models (Smith et al., 2002; Richens et al., 2009), as well
as in a Rtp801 knockout model for side stream smoke (Yoshida
et al., 2010). This is reflected in the success of superoxide dismu-
tase (SOD) transgenic mice (Foronjy et al., 2006; Richens et al.,
2009), specifically those with enhanced SOD3 expression (Yao
et al., 2010), in protecting against emphysema in both exposure
scenarios.
WHAT IS MISSING
Unfortunately, even with chronic exposure studies, the animal
model has limitations to how well it can mimic COPD, as seen by
the inadequacy of interventions that protect mice against cigarette
smoke induced emphysema, but not humans (Barnes, 2007). A
procedure that is applied in the same way for each study could
greatly contribute to our understanding of pathogenesis and how
the animal model relates to the human disease. For example, with
a standard 6-month exposure period for mouse models, research
groups have been able to establish a disease time frame that is uti-
lized for most chronic studies. In rats, this chronic period starts at
2months of exposure (Ofulue et al., 1998; Kratzer et al., 2013) and
in guinea pigs after 3 months of exposure (Wright et al., 2002).
In order to truly compare results, though, it is of importance to
standardize exposure methods and levels as well.
Generally, there is favoritism toward the somewhat more
recent application of chambers, which was greatly improved so
as to be utilized as a standard method for SHS exposure in 1994
(Teague et al., 1994). A chamber may contain any number of
animals and is often applied to produce a cigarette smoke mix-
ture consisting of 89% side stream and 11% mainstream smoke,
exposing animals to environmental smoke versus attaching a nose
or head piece to introduce smoke first hand. Often, though, even
mainstream or side stream smoke exposure are neglected to be
pointed out, as it is assumed that using a chamber method should
suffice as information, even though it can require extensive back-
referencing to discover the actual original procedure. Beyond the
smoke chamber, which wasn’t developed until 1994 (Teague et al.,
1994), few standardized procedures were possible. Since then,
though, there is still very little homogeneity in the applications
used for research in this field. We could greatly improve our
understanding of the consequences of inhaled cigarette smoke
if we were to apply a similar and comparable model in every
case. This would require selecting conform research cigarettes,
whether filtered or not, preferably from the same source, so that
contents and levels of important toxins and mediators can be
compared.
If a variety of cigarettes are necessary to accommodate research
across the globe, it is imperative that at least cigarette param-
eters are assessed and noted. Reference cigarettes were specif-
ically designed from 1969 onwards for the purpose homoge-
nous and comparable studies around the world. To this day,
commercial cigarettes with varying or unknown parameters are
applied.
There is still an abundance of publications that do not men-
tion or may even not determine nicotine or carbon monoxide
amounts or the contributing particles in cigarettes (whether as
TSP or TPM), though it could easily be evaluated from online
supplements for major cigarettes in use. For randomly selected
commercial cigarettes, of course, there is not even this option,
as only nicotine and in very few cases carbon monoxide levels
are available. Some studies do not even list the cigarette type or
brand used, so there is practically no information concerning the
exposure. These factors complicate matters even further, as there
are already numerous ways that cigarette smoke is administered,
using as few as two cigarettes a day in mice (Hautamaki et al.,
1997; Shapiro et al., 2003) or as many as 12 cigarettes a day in rats
(Nie et al., 2012).
Additionally,many studies use an initial acclimation period for
their cigarette smoke exposure, employing an increasing num-
ber of cigarettes or longer smoke periods after beginning the
study, thereby also allowing variability, but acclimation is usually
necessary. Inconsistencies can be avoided by assessing the most
important parameters, such as nicotine, carbon monoxide, and
particle levels. If the scientific community could agree on a pro-
tocol to establish similar exposures both for mainstream and side
stream cigarette smoke, results would be much more comparable.
At a bare minimum, simply correctly documenting the method
used would add a great deal to the knowledge that could have
already been gained. In this way, cigarette smoke researchers all
around the world would be able to collectively assess and compare
their data.
CONCLUSION
Cigarette smoke exposure is the most important risk factor for
developing COPD, both in smokers and in non-smokers who
are involuntarily exposed to the toxic and carcinogenic con-
tents of environmental cigarette smoke. Studies of long-term
cigarette smoke exposure effects are very costly, time-consuming,
and require an abundance of resources. For this reason, tests
should be optimized so that experimental models are compara-
ble and provide as much knowledge as possible. It is evident from
the literature that there is, to this day, enormous unnecessary
diversity in study designs despite improvements to our experi-
mental exposure methods (chambers and reference cigarettes).
There is a great need for a standard protocol defining parame-
ters to be evaluated and exposure procedures to be followed. With
this quite simple documentation of easily assessed facts and we
would be able to gain much more knowledge with each study. It
should be possible to determine molecular mechanisms, oxida-
tive stress, protease participation, inflammatory cytokine levels,
and cellular death following mainstream and side stream cigarette
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smoke exposure, comparing them. These insights would greatly
improve and expand today’s comprehension of cellular and
molecular mechanisms implicated in the pathology of COPD.
A more defining knowledge of the pathogenesis of mainstream
and second hand cigarette smoke induced emphysema, SAR,
and pulmonary hypertension could have been achieved with the
undertaken studies if a unified procedural method had been
applied.
Despite the shortcomings in terms of documentation in a
large amount of experiments, they have nonetheless led to great
advances through gene knockout models or transgenic mice as
well as inhibitory tactics and drug treatments. When combining
these animal studies in one overview, it becomes highly evident
that second hand cigarette smoke has many of the same mecha-
nisms and detrimental effects that mainstream smoke does. For
this reason, we wish to point out that the US Surgeon General’s
assessment of a missing link should be revisited, so that the pub-
lic becomes more aware of the health risks to innocent bystanders,
where SHS exposure causes COPD/emphysema in non-smokers.
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